



## Phospholipase A<sub>2</sub>-Dependent and -Independent Pathways of Arachidonate Release from Vascular Smooth Muscle Cells

Agnès Cane, Michelyne Breton, Gilbert Béréziat and Odile Colard\*

CNRS URA-1283, CHU SAINT-ANTOINE, 27 RUE CHALIGNY, 75012, PARIS, FRANCE

**ABSTRACT.** [Arg<sup>8</sup>]vasopressin (AVP), through its V<sub>1</sub> receptor coupled to GTP-binding proteins, and aluminum fluoride (AlF<sub>4</sub><sup>-</sup>), which directly activates GTP-binding proteins, induced the release of [<sup>3</sup>H]arachidonate from prelabeled A<sub>7</sub>R<sub>5</sub> vascular smooth muscle-like cells. Using fura-2-loaded cells, we observed that the release induced by AVP occurred concurrently with calcium (Ca<sup>2+</sup>) mobilization from internal stores and entry of external Ca<sup>2+</sup>, whereas AlF<sub>4</sub><sup>-</sup>-dependent arachidonate release was much slower and was not accompanied by intracellular Ca<sup>2+</sup> mobilization. Arachidonate transfer from phosphatidylcholine to phosphatidylethanolamine was an early event for both agonists, but phosphatidylinositol hydrolysis was an early event for AVP-stimulated cells and a late event for cells triggered with AlF<sub>4</sub><sup>-</sup>. In addition, phospholipase inhibitors had no effect on arachidonate release induced by AlF<sub>4</sub><sup>-</sup>. We investigated the enzymatic pathways involved in the releases of arachidonate, which occur in such different ways. Phospholipase A<sub>2</sub> activities were assayed in a cell-free system with various substrates, which made it possible to differentiate between cytosolic, secretory and Ca<sup>2+</sup>-independent phospholipases A<sub>2</sub>. The specific activities were in the order alkenyl-AA-GPE > acyl-AA-GPE > acyl-AA-GPC in the presence of Ca<sup>2+</sup>. No significant activity was observed in the presence of Ca<sup>2+</sup> chelators and when dipalmitoyl-glycerophosphocholine was used as a substrate. Phospholipase A<sub>2</sub> activities did not change in homogenates from stimulated cells related to control cells. However, phospholipase A<sub>2</sub> activity increased in membrane fractions from AVP-stimulated cells. Immunodetected phosphorylated and unphosphorylated forms of cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) also clearly increased in the membrane fractions of AVP-stimulated cells, and only the unphosphorylated form of cPLA<sub>2</sub> was present in AlF<sub>4</sub><sup>-</sup>-triggered cells. We conclude that phospholipase C and translocation of cPLA<sub>2</sub> can account for arachidonate release with AVP stimulation, whereas neither phospholipase C nor any phospholipase A<sub>2</sub> activity appears to be implicated in AlF<sub>4</sub><sup>-</sup>-dependent arachidonate release. Copyright © 1997 Elsevier Science Inc. BIOCHEM PHARMACOL 53;3:327–337, 1997.

**KEY WORDS.** arachidonic acid; cytosolic phospholipase A<sub>2</sub>; [Ca<sup>2+</sup>]<sub>i</sub>; phospholipid hydrolysis; vascular smooth muscle cells; vasopressin; aluminum fluoride.

Proliferation of VSMC† plays a crucial role in the pathogenesis of hypertension and atherosclerosis [1]. AA and/or its cyclooxygenase or lipoxygenase metabolites have recently been shown to modulate the expression of early growth-responsive genes in fibroblasts [2] and in VSMC [3]

and to activate mitogen-activated protein kinases [4]. Very low levels of free AA in resting cells are maintained by rapid incorporation and remodeling in cellular lipids [5, 6], and AA has to be released from phospholipid stores to be transformed into biologically active metabolites. AA release from inflammatory cells in response to receptor stimulation occurs concurrently to an increase in intracellular calcium, through Ins(1,4,5)P<sub>3</sub> formation and Ca<sup>2+</sup> channel opening [7]. Therefore, Ca<sup>2+</sup>-dependent PLA<sub>2</sub>s were thought to be involved in AA release. Two well-described PLA<sub>2</sub>s are candidates: the 85-kDa cPLA<sub>2</sub> and the 14-kDa sPLA<sub>2</sub>. The cPLA<sub>2</sub> is activated with phosphorylation by MAP kinases [8, 9] and translocated to membranes by micromolar Ca<sup>2+</sup> concentrations [10–12]. GTP-binding proteins would be involved in the coupling of cPLA<sub>2</sub> to the receptor [13]. The sPLA<sub>2</sub> requires a millimolar Ca<sup>2+</sup> concentration to be active [14]. The cPLA<sub>2</sub> is specific for AA-containing phospholipids [10, 15–16], whereas sPLA<sub>2</sub> prefers phosphatidylethanolamine as a substrate with no fatty

\* Corresponding author: Dr. Odile Colard, CNRS URA-1283, CHU Saint-Antoine, 27 Rue Chaligny, 75012 Paris, France. TEL: (33) 01 40 01 13 40; FAX: (33) 01 40 01 14 99.

† Abbreviations: VSMC, vascular smooth muscle cells; AVP, [Arg<sup>8</sup>]vasopressin; AA, arachidonic acid; [Ca<sup>2+</sup>]<sub>i</sub>, cytosolic-free calcium concentration; PLA<sub>2</sub>, phospholipase A<sub>2</sub>; cPLA<sub>2</sub>, cytosolic phospholipase A<sub>2</sub>; sPLA<sub>2</sub>, secretory phospholipase A<sub>2</sub>; iPLA<sub>2</sub>, Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub>; GPE, glycerophosphoethanolamine; GPC, glycerophosphocholine; AlF<sub>4</sub><sup>-</sup>, aluminum fluoride; [<sup>3</sup>H]AA, [<sup>3</sup>H] arachidonic acid; alkenyl-[<sup>3</sup>H]AA-GPE, 1-alkenyl-2-[<sup>3</sup>H]arachidonyl-GPE; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; DTT, dithiothreitol; TBS, Tris buffered saline; Mops, 3-[N-morpholin]propane-sulfonic acid; BSA, bovine serum albumin; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; DPPC, dipalmitoylphosphatidylcholine.

Received 28 May 1996; accepted 28 August 1996.

acid specificity [14]. Both phospholipases are involved in AA release in a number of cell systems [17–23], thus strengthening the idea of an absolute requirement of calcium for AA release.

However, treatment of endothelial cells with the GTP-binding protein activator  $\text{AlF}_4^-$  resulted in the release of a large pool of AA that did not depend on the presence of extracellular  $\text{Ca}^{2+}$  or on the mobilization of intracellular  $\text{Ca}^{2+}$  [24, 25]. In other respects,  $\text{Ca}^{2+}$ -iPLA<sub>2</sub> has been described in VSM-like cells [26] and macrophage-like cells [27]. In A<sub>10</sub> VSM-like cells, involvement of iPLA<sub>2</sub> in AA release induced by AVP was deduced from inhibition of AA release by using a specific iPLA<sub>2</sub> inhibitor [26]. The AA release triggered by AVP from VSMC also implicates multiple signaling pathways such as phosphatidylinositol and phosphatidylcholine phospholipases C [28–30], GTP-binding proteins [30], mitogen-activated protein kinases [31], phospholipase D [31, 32] and ionic channels [33].

To investigate  $\text{Ca}^{2+}$ -dependent and -independent pathways of AA release, we used the A<sub>7r5</sub> VSMC line that we triggered with AVP or  $\text{AlF}_4^-$ . The differences observed for the receptor-dependent agonist and the pharmacological tool in the kinetics and calcium dependence of AA release and in phospholipid hydrolysis suggested the implication of different enzymatic pathways. We demonstrate that  $\text{Ca}^{2+}$ -dependent translocation of cPLA<sub>2</sub> could be responsible, at least in part, for the AVP-induced AA release, whereas the AA release induced by  $\text{AlF}_4^-$  is independent of  $\text{Ca}^{2+}$  and does not involve any PLA<sub>2</sub> activity.

## MATERIALS AND METHODS

### Materials

[<sup>3</sup>H]AA (200 Ci/mmol), 1-stearoyl-2-[1-<sup>14</sup>C]arachidonyl-phosphatidylcholine (54 mCi/mmol), 1-palmitoyl-2-[1-<sup>14</sup>C]palmitoyl-phosphatidylcholine (59 mCi/mmol) and 1-acyl-2 [1-<sup>14</sup>C]arachidonyl-phosphatidylethanolamine (55 mCi/mmol) were purchased from Amersham (Buckinghamshire, UK); 1-alkenyl-2-[<sup>3</sup>H]arachidonyl-phosphatidylethanolamine (83 mCi/mmol) was purified from U<sub>937</sub> cells labeled with [<sup>3</sup>H]AA. Briefly,  $50 \times 10^6$  cells were incubated with 110  $\mu\text{Ci}$  [<sup>3</sup>H]AA for 8 hr. The cells were then scraped in cold PBS, and the lipids were extracted by the procedure of Bligh and Dyer [34]. During this period of time, 90% of the initial AA were incorporated in cell lipids and 32% were esterified in ethanolamine-containing phospholipids. The lipid extract was then treated with phospholipase A<sub>1</sub> from *Rhizopus Arrhizus* (5 UI/ $\mu\text{mol}$ ) to remove the diacyl phospholipids [35]. After extraction, the remaining ether-phosphatidylethanolamine pool was purified on a silicic acid column. The column was washed first with chloroform/methanol/ $\text{NH}_4\text{OH}$  (20%) (90:10:0.02, v/v/v) [36], and the ether-phosphatidylethanolamine fraction was eluted with chloroform/methanol/ $\text{NH}_4\text{OH}$  (60:10:0.02, v/v/v). The substrate was free from any compound acylated on the sn1 position of the glycerol but contained approximately 20% 1-alkyl-2-[<sup>3</sup>H]AA-GPE as determined by treat-

ment with HCl fumes, the remaining compound being alkenyl-[<sup>3</sup>H]AA-GPE. The specific activity of 1-alkyl- plus alkenyl-[<sup>3</sup>H]AA-GPE compounds, as determined from phosphorus assay [37] and radioactivity counting, was 83 mCi/mmol.

AVP, NaF,  $\text{AlCl}_3$ , ATP, BAPTA, EGTA, PMSF, DTT, leupeptine, bacitracine, benzamidine, Mops, quinacrine, neomycin, fatty-acid-free BSA, unlabeled phospholipids and AA were obtained from Sigma. Fura-2/AM was obtained from Molecular Probes (Eugene, OR, USA). Lipase from *Rhizopus arrhizus* was obtained from Boehringer-Mannheim (Mannheim, Germany). DMEM, PBS, FCS, glutamin, penicillin, streptomycin and trypsin/EDTA were purchased from Gibco (Grand Island, NY, USA). Silica gel 60 HPTLC was purchased from Merck (Darmstadt, Germany). Silica gel TLC and nitrocellulose membranes were obtained from Schleicher and Schuell (Dassel, Germany). Rabbit polyclonal anti cPLA<sub>2</sub> antibody was obtained from Santa-Cruz Biotechnology Inc. (Santa-Cruz, CA, USA) and anti-rabbit IgG (H+L) horseradish peroxidase conjugated was obtained from Biorad (Hercules, CA, USA).

### Cell Culture and [<sup>3</sup>H]AA Release

Rat aortic A<sub>7r5</sub> smooth muscle cells were obtained from the European Collection of Animal Cell Cultures (ECACC; Salisbury, UK). The cells were grown at 37°C in DMEM supplemented with 10% (v/v) FCS, 2 mM glutamin, 100 U/mL penicillin and 100  $\mu\text{g}/\text{mL}$  streptomycin (DMEM/FCS) under a 5%  $\text{CO}_2$  atmosphere. A<sub>7r5</sub> cells were subcultured every 7 days using trypsin/EDTA in 75-cm<sup>2</sup> flasks. For experiments, cells between passages 4–30 were seeded into 35- or 60-mm dishes and used at confluence.

To measure AA release, A<sub>7r5</sub> cells grown in 6-well plates ( $10^5$  cells/well), were incubated with [<sup>3</sup>H]AA (0.2  $\mu\text{Ci}/\text{well}$ ) for 1 hr in 1 mL of DMEM/FCS. We determined that approximately 30–40% of [<sup>3</sup>H]AA was incorporated in cells during the 60-min incubation period. The medium was removed and nonincorporated [<sup>3</sup>H]AA was determined. Cells were washed twice with 1 mL of DMEM/FCS to eliminate free [<sup>3</sup>H]AA. Prelabeled cells were then incubated with inhibitors or/and stimulated by the agonists AVP (1  $\mu\text{M}$ ) or  $\text{AlF}_4^-$  (5 mM NaF and 10  $\mu\text{M}$   $\text{AlCl}_3$ ) at 37°C for different periods of time in 2 mL of DMEM/FCS. Supernatants were removed and released radioactivity was measured by counting in Ready Safe scintillation mixture on an LS-6000-SC counter (Beckman Instruments, Inc., Palo Alto, CA, USA) and expressed as a percentage related to initial incorporation. The noncytotoxicity of 2 hr exposures to  $\text{AlF}_4^-$  (5 mM NaF and 10  $\mu\text{M}$   $\text{AlCl}_3$ ) was verified by the neutral red method [38].

### Measurement of Intracellular Calcium

$[\text{Ca}^{2+}]_i$  was monitored using fura-2 as a fluorescent  $\text{Ca}^{2+}$  indicator. Confluent monolayers of A<sub>7r5</sub> cells attached to a glass coverslip were loaded with fura-2 by incubating them

with 2–4  $\mu$ M fura-2-acetoxymethylester for 90–120 min at room temperature in control medium containing 140 mM NaCl, 6 mM KCl, 1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM Hepes pH 7.4 and 10 mM glucose. Loaded cells were washed three times and then incubated with the same buffer for an additional 20 min to hydrolyze completely the entrapped ester. The slides were then placed in the heated (30°C) compartment of the spectrofluorimeter. [Ca<sup>2+</sup>]<sub>i</sub> was measured under magnetic stirring in a fluorescence spectrophotometer constructed by Cairn Research Ltd. (Newnham, Sittingbourne, Kent, UK), which allows simultaneous excitation of fluorescence at 340 and 380 nm. Fluorescence emission was set at 530 nm. Fluorescence readings were integrated at every 1-sec period, and [Ca<sup>2+</sup>]<sub>i</sub> was calculated from the ratio of fluorescence excited at 340 and 380 nm. During the experiment, the solution bathing the cells (flow rate of 2 mL/min) was changed by perfusing fresh solution into the bottom of the cuvette while aspirating continuously from just above the coverslip [39].

To follow Mn<sup>2+</sup> entry and quenching of fura-2 fluorescence, cells were superfused with Ca<sup>2+</sup>-free buffer containing 200  $\mu$ M MnCl<sub>2</sub>. Fluorescence was followed at 530 nm and cells excited at 360 nm, a wavelength insensitive to changes in [Ca<sup>2+</sup>]<sub>i</sub> [39].

### [<sup>3</sup>H]AA Repartition in Phospholipids

Following incubation with radiolabel, stimulation with agonists and removal of the supernatants to quantify the arachidonic acid release, cells were scraped in 1 ml of cold methanol and 800  $\mu$ L of water. Lipids were extracted as previously described and spotted on HPTLC plates. The first mobile phase consisted of chloroform/methanol/acetic acid/water (75:45:12:6, v/v/v/v) for 25 min and the second phase of petroleum ether (40–65°C)/diethylether/acetic acid (70:30:1, v/v/v) for 15 min, both in the same dimension. The first dimension separated phosphatidylcholine, phosphatidylinositol/phosphatidylserine and phosphatidylethanolamine and the second separated fatty acids, diglycerides and triglycerides. Lipids were visualized by autoradiography and identified by their comigration with standards by staining with iodine vapor. The bands were scraped from the plates and counted for radioactivity.

### Preparation of Subcellular Fractions

Cells in 75-cm<sup>2</sup> flasks were stimulated with AVP (1  $\mu$ M for 10 min) or AIF<sub>4</sub><sup>−</sup> (5 mM NaF and 10  $\mu$ M AlCl<sub>3</sub> for 120 min) in 5 mL of DMEM/FCS at 37°C. The stimulation was stopped by aspirating media and adding 2 mL trypsin/EDTA. The cells were diluted in DMEM/FCS and then washed twice with PBS. Cell pellets were suspended in 500  $\mu$ L of buffer containing 25 mM Tris, 125 mM KCl, 5 mM MgCl<sub>2</sub>, 1 mM ATP, pH 9.6 and protease inhibitors (0.5 mM PMSF, 50  $\mu$ M leupeptine, 50  $\mu$ g/mL benzamidine, 50  $\mu$ g/mL bacitracine). Cells were lysed by N<sub>2</sub> cavitation (600 psi, 20 min, 4°C) in the presence of 2 mM CaCl<sub>2</sub> or 2 mM

EGTA. Nucleus and intact cells were removed by centrifugation at 600g for 10 min at 4°C. Supernatants were further diluted v/v with Hepes buffer (4.2 mM Hepes, 137 mM NaCl, 2.6 mM KCl, 1 mg/mL glucose, pH 7.4) and centrifuged at 100,000g for 60 min at 4°C. Cytosols were aliquoted and stored at −80°C. Membrane pellets were resuspended in Hepes buffer, sonicated 2 × 10 sec at step 6 in MSE probe sonicator and stored at −80°C until used for PLA<sub>2</sub> assays. Proteins were determined according to Bradford [40], using BSA as standard.

### Measurements of PLA<sub>2</sub> Activities

To differentiate between various cytosolic, secretory and Ca<sup>2+</sup>-independent PLA<sub>2</sub> activities, we used different substrates and assays. Hydrolysis of three arachidonate-labeled substrates, 1-alkenyl-2-[<sup>3</sup>H]AA-GPE, 1-acyl-2-[<sup>14</sup>C]AA-GPE and 1-acyl-2-[<sup>14</sup>C]AA-GPC, was assayed using mixed micelles composed of labeled substrate, egg yolk phosphatidylcholine and Triton X-100 [41]. Briefly, the radiolabeled substrate was mixed with egg yolk phosphatidylcholine in a ratio of 3:1 and evaporated to dryness. The residues were resuspended in Mops buffer (0.1 M, pH 7.4) containing Triton X-100 and sonicated twice for 15 sec. The reaction mixture contained 2  $\mu$ M sonicated phospholipids, 200  $\mu$ M Triton X-100, 0.25 mg/mL fatty-acid-free BSA, 2 mM DTT, 5 mM CaCl<sub>2</sub> and 2–5  $\mu$ g protein in a total volume of 0.25 mL of Mops buffer containing 20% glycerol. In some experiments devoted to sPLA<sub>2</sub>, concentration of DTT was 0–10 mM. In other experiments designed to assay iPLA<sub>2</sub>, CaCl<sub>2</sub> was omitted and incubations were performed in the presence of 2 mM EGTA. Following incubation at 37°C for 30 min, the reaction was stopped by adding 960  $\mu$ L chloroform/methanol (1:2, v/v), and the lipids were extracted by the procedure of Bligh and Dyer [34]. The lipidic extract was separated on TLC plates developed in the solvent system petroleum ether (40–65°C)/diethylether/acetic acid (70:30:1, v/v/v) for 15 min and exposed to I<sub>2</sub> vapor. AA (10  $\mu$ g) was added as a carrier. The spots corresponding to AA and phospholipids were scraped and counted for radioactivity.

Phospholipase A<sub>2</sub> assay using DPPC was performed as described by Ackerman *et al.* [42]. The incubation medium contained 400  $\mu$ M Triton X-100, 10 or 100  $\mu$ M DPPC and 2 × 10<sup>5</sup> dpm 1-palmitoyl-2-[<sup>14</sup>C]palmitoyl-GPC, 0.1 M Hepes pH 7.5, 5 mM EDTA, 0.8 mM ATP in 250  $\mu$ L final volume. The substrate was prepared by resuspending the dried phospholipids in 100  $\mu$ L Hepes buffer containing Triton X-100 and EDTA. Mixed micelles were formed by heating (above 40°C) and sonication with an MSE probe sonicator. The incubation was performed at 40°C for 60 min. The reaction was stopped by adding chloroform/methanol and subsequently processed as for the previously described assays.

### Immunoblotting Analysis

Control or stimulated cells (7.5 × 10<sup>5</sup> cells) were washed with 3 × 10 mL of ice-cold PBS, scraped in 300  $\mu$ L of 25

mM Hepes buffer pH 7.4 containing 5 mM EDTA, 50 mM NaF, 100  $\mu$ M sodium orthovanadate, 1 mM PMSF and 10  $\mu$ g/mL leupeptine (lysis buffer) and homogenized by passing repeatedly through a 25-G needle. Cytosol and membrane fractions were separated by centrifugation at 100,000g and 4°C, and pellets were resuspended in 300  $\mu$ L of lysis buffer. Cell extracts ( $1.25 \times 10^5$  cells equivalent per lane) were boiled for 5 min in Laemmli buffer [43], and proteins were resolved by a 7.5% SDS-PAGE. Following electrophoresis, gels were equilibrated for 10 min in transfer buffer [25 mM Tris, 192 mM glycine and 20% (v/v) methanol]. Proteins were transferred onto 0.2- $\mu$ m nitrocellulose membranes for 2 hr at 200 mA, using a semidry transfer unit (Hoefer, San Francisco, CA, USA), and membranes were stained with Ponceau S to verify efficient and equal transfer of protein samples. The membranes were then blocked overnight with 3% (w/v) BSA in TBS containing 50 mM Tris pH 7.2, 150 mM NaCl and 0.1% (v/v) polyoxyethylenesorbitan monolaurate (Tween 20). After washing with TBS, membranes were probed with rabbit polyclonal antibody to cPLA<sub>2</sub> (diluted 1:50) for 2 hr. After washing with TBS, membranes were treated with peroxidase-conjugated goat anti-rabbit secondary antibody (diluted 1:1000) for 1 hr, and peroxidase activity was detected by using enhanced chemiluminescence reagents (Amersham Corp.). Human cPLA<sub>2</sub> was overexpressed using the baculovirus-insect cell expression system [44]. Cytosol from infected cells was used as standard.

## RESULTS

Both AVP and AIF<sub>4</sub><sup>-</sup> were potent activators of AA release from A<sub>7</sub>r<sub>5</sub> cells incubated in the presence of FCS. Preliminary experiments showed that maximum release was observed with 1  $\mu$ M AVP from cells prelabeled with [<sup>3</sup>H]AA for 1 hr. Exposure to AIF<sub>4</sub><sup>-</sup> involved 5 mM NaF and 10  $\mu$ M AlCl<sub>3</sub>. The time course of AA release was completely different depending on the agonist (Fig. 1). The AVP response was immediate. The release of AA increased very rapidly during the first 3 min and more slowly up to 30 min, when it represented 10% of total lipid labeling. In contrast, a 30-min latent period was required after AIF<sub>4</sub><sup>-</sup> addition. The release of AA was then linear up to 120 min when it represented 20% of lipid labeling.

To determine the Ca<sup>2+</sup> dependence of AA release from A<sub>7</sub>r<sub>5</sub> cells, we used EGTA to chelate extracellular calcium and/or BAPTA to chelate intracellular calcium. The results indicate that the presence of 2 mM EGTA and/or 10  $\mu$ M BAPTA decreased AA release induced by AVP in DMEM/FCS by 70–80% (Fig. 2). These data suggest that an influx of extracellular calcium and calcium release from endogenous pools are required for AA release by AVP. Figure 2 also shows that chelation of intracellular calcium with 10  $\mu$ M BAPTA did not affect AIF<sub>4</sub><sup>-</sup>-induced AA release, whereas chelation of extracellular calcium by EGTA reduced AA release by more than 50%. These results suggest




FIG. 1. Time course of AVP- and AIF<sub>4</sub><sup>-</sup>-stimulated AA release from A<sub>7</sub>r<sub>5</sub> cells. Cells prelabeled with 0.2  $\mu$ Ci of [<sup>3</sup>H]AA for 60 min were treated as described in Materials and Methods in DMEM/FCS control medium (open squares), with 1  $\mu$ M AVP (triangles) or with AIF<sub>4</sub><sup>-</sup> (5 mM NaF and 10  $\mu$ M AlCl<sub>3</sub>; circles). Data represent mean values  $\pm$  SEM of five determinations.

that almost half of the AIF<sub>4</sub><sup>-</sup>-induced AA release involved a calcium-independent pathway and did not depend on a rise in intracellular calcium.

The cytosolic Ca<sup>2+</sup> levels observed after stimulation with AVP or AIF<sub>4</sub><sup>-</sup> confirmed the results obtained with the calcium chelators. A<sub>7</sub>r<sub>5</sub> cells were loaded with the calcium-sensitive dye fura-2, and the fluorescent signal at 340 and 380 nm was monitored over time by using single cells.

When cells were stimulated with 1  $\mu$ M AVP in the




FIG. 2. Effects of extracellular and intracellular Ca<sup>2+</sup> chelations on AVP- and AIF<sub>4</sub><sup>-</sup>-stimulated AA release. [<sup>3</sup>H]AA prelabeled A<sub>7</sub>r<sub>5</sub> cells were stimulated with AVP (1  $\mu$ M) or AIF<sub>4</sub><sup>-</sup> (5 mM NaF and 10  $\mu$ M AlCl<sub>3</sub>) for the indicated periods of time in DMEM/FCS control medium or in DMEM/FCS containing 2 mM EGTA; 10  $\mu$ M BAPTA was preincubated with cells for 10 min prior to addition of the agonists. Data represent the percent of [<sup>3</sup>H] radioactivity release and are mean values  $\pm$  SD of two determinations.

absence of extracellular calcium ( $0 \text{ Ca}^{2+}$ ), we observed a very sharp increase in  $[\text{Ca}^{2+}]_i$ , reaching a maximum between 600 and 800 nM and returning to baseline level within 40–60 sec after stimulation (Fig. 3A). When the same experiment was done in the presence of 1 mM extracellular calcium,  $[\text{Ca}^{2+}]_i$  reached 1  $\mu\text{M}$  and the peak became wider, perhaps corresponding to an entry of extracellular calcium. To confirm this hypothesis, a parallel experiment was carried out to monitor the influx of  $\text{Mn}^{2+}$ , which enters cells via the same channels as  $\text{Ca}^{2+}$  [39]. When  $\text{Mn}^{2+}$  enters the cell, it combines with fura-2 and quenches its fluorescence. Figure 3C shows a continuous decrease in the fura-2 fluorescent signal at 360 nm when cells were stimulated with AVP in the presence of 100  $\mu\text{M}$   $\text{MnCl}_2$ . These data suggest that AVP induced an influx of extracellular calcium by opening calcium channels in the plasma membranes. Both intracellular calcium mobilization and extra-

cellular calcium entry then occurred in smooth muscle cells stimulated with AVP.

When cells were triggered with  $\text{AlF}_4^-$ , there was very little effect on  $[\text{Ca}^{2+}]_i$  (Fig. 3B). The slight increase in fluorescence observed after  $\text{AlF}_4^-$  addition could correspond to a slight influx of extracellular calcium and thereby account for the effect of EGTA on AA release.

Labeled AA was rapidly incorporated into cell lipids and approximately 30–40% of initial radioactivity was esterified after 60 min. Following this period, more than 70% of esterified  $[\text{H}]\text{AA}$  was recovered in phosphatidylcholine and phosphatidylinositol, whereas approximately 20% was esterified in phosphatidylethanolamine (Fig. 4). Under control conditions,  $[\text{H}]\text{AA}$  was slowly redistributed from phosphatidylcholine to phosphatidylethanolamine. When cells were stimulated by 1  $\mu\text{M}$  AVP, we observed a rapid hydrolysis of phosphatidylinositol, which paralleled the re-




FIG. 3. Effects of AVP and  $\text{AlF}_4^-$  on  $[\text{Ca}^{2+}]_i$  in  $A_7r_5$  cells. Cells were grown to confluence on a glass coverslip, loaded with 2–4  $\mu\text{M}$  fura-2/AM for 90–120 min at room temperature and placed in a cuvette. Cytosolic  $\text{Ca}^{2+}$  concentrations ( $[\text{Ca}^{2+}]_i$ ) were monitored continuously as buffer was perfused through a cuvette at 2 mL/min and 37°C. (A) AVP (1  $\mu\text{M}$ ) or (B)  $\text{AlF}_4^-$  (5 mM NaF and 10  $\mu\text{M}$   $\text{AlCl}_3$ ) was added to perfusion in medium containing 1 mM  $\text{CaCl}_2$  as indicated. (C) 100  $\mu\text{M}$   $\text{MnCl}_2$  was added to cells before stimulation by AVP. These traces represent five experiments.

lease of AA in the medium, followed by a large transfer of [ $^3\text{H}$ ]AA to phosphatidylethanolamine. In response to  $\text{AlF}_4^-$ , a large transfer of AA from phosphatidylcholine to phosphatidylethanolamine, largely preceding the release of arachidonate, was observed. Thereafter, the release of [ $^3\text{H}$ ]AA seemed to be correlated with hydrolysis of phosphatidylinositol (Fig. 4).

The mechanisms by which either AVP or  $\text{AlF}_4^-$  liberate AA from  $\text{A}_{7\text{r}5}$  VSMC appear to be completely different because we observed different time courses, calcium dependencies and phospholipid hydrolysis. We then investigated the enzymes that could be responsible for AA release induced by AVP or  $\text{AlF}_4^-$ .

Preincubation of cells with quinacrine or neomycin, widely used as inhibitors of  $\text{PLA}_2$  and phospholipase C, respectively, reduced the AVP-stimulated AA release by approximately 50%, whereas these compounds did not modify the AA release induced by  $\text{AlF}_4^-$  (Fig. 5). Because neomycin binds to phosphatidylinositol mono- and biphosphates, thus preventing their hydrolysis by phospholipase

C, its absence of effect in  $\text{AlF}_4^-$ -triggered cells suggests that phospholipase C is not involved in phosphatidylinositol hydrolysis following  $\text{AlF}_4^-$  addition. The mechanism of action of quinacrine is not clearly elucidated, but this compound inhibits AA release in a number of cell systems. Again, it had no effect in  $\text{AlF}_4^-$ -triggered cells, suggesting that classical  $\text{PLA}_2$  was not implicated.

Low-molecular-mass  $\text{sPLA}_2$  [45] and high-molecular-mass  $\text{cPLA}_2$  [46] have been described in rat VSMC. In addition, the presence of  $\text{iPLA}_2$  has been deduced from the inhibitory effect of a bromoenolactone, a specific  $\text{iPLA}_2$  inhibitor, on agonist-induced AA release from  $\text{A}_{10}$  cells, a rat VSMC clone [26]. It was then of interest to determine which  $\text{PLA}_2$ s were present in our  $\text{A}_{7\text{r}5}$  cell line.  $\text{sPLA}_2$  is sensitive to reducing agents [14] and specific for diacyl-GPE hydrolysis over diacyl-GPC [14], whereas  $\text{cPLA}_2$  is specific for arachidonate-containing phospholipids [10, 15, 16]. The  $\text{iPLA}_2$  would preferentially hydrolyze plasmalogen phospholipids [47]. Therefore, we investigated  $\text{PLA}_2$  activities in a cell-free system using three different arachidonate-




FIG. 4. Time course of [ $^3\text{H}$ ]AA release and movements in the major lipid classes of  $\text{A}_{7\text{r}5}$  cells. Cells were incubated in DMEM/FCS in presence of  $0.2 \mu\text{Ci}$  of [ $^3\text{H}$ ]AA for 1 hr. After washing, the prelabeled cells were incubated in DMEM/FCS (open squares), DMEM/FCS plus AVP (triangles) or  $\text{AlF}_4^-$  (circles) for the indicated periods of time. Radioactivity released in supernatant was counted and cells were extracted for lipid HPTLC analysis as described in Materials and Methods. The bands were identified by standard comigration, stained by  $\text{I}_2$  vapor, scraped and counted for radioactivity. (PE, phosphatidylethanolamine; PI, phosphatidylinositol; PC, phosphatidylcholine). The data are expressed as a percentage of total radioactivity and represent three independent experiments.




FIG. 5. Effects of phospholipase inhibitors on AVP- and AIF<sub>4</sub><sup>-</sup>-stimulated AA release. Cells prelabeled with [<sup>3</sup>H]AA were treated by 5  $\mu$ M quinacrine or 2 mM neomycin for 10 min prior to addition of the agonists in DMEM/FCS control medium. Release of [<sup>3</sup>H]AA was performed as described in Materials and Methods. Values are the means  $\pm$  SEM of two experiments.

labeled substrates: diacyl-GPE, alkenyl-acyl-GPE and diacyl-GPC. To minimize the effects due to different physical conformations of the various substrates, mixed micelles containing egg phosphatidylcholine and Triton X-100 with labeled substrate were always used.

Table 1 shows that in the presence of calcium the A<sub>7</sub>R<sub>5</sub> lysate from control cells hydrolyzed the three substrates in the order of preferential hydrolysis: alkenyl-acyl-GPE > diacyl-GPE > diacyl-GPC. The hydrolysis of the various substrates was not inhibited by the presence of DTT in the incubation medium. The insensitivity to reducing agent and the absence of sPLA<sub>2</sub> secretion (data not shown) exclude the involvement of sPLA<sub>2</sub> in the release of AA by the A<sub>7</sub>R<sub>5</sub> cell line. In the absence of calcium, hydrolysis represented less than 10% of the hydrolysis observed in Ca<sup>2+</sup>-containing medium, whatever the substrate. Thus it was

TABLE 1. Substrate specificity of PLA<sub>2</sub> activity (pmol/mg/min) in A<sub>7</sub>R<sub>5</sub> cells

	Control	AVP for 10 min	AIF <sub>4</sub> <sup>-</sup> for 120 min
Acyl-[ <sup>14</sup> C]AA-GPC (n = 2)	294 $\pm$ 26	260 $\pm$ 32	
Acyl-[ <sup>14</sup> C]AA-GPE (n = 8)	439 $\pm$ 34	385 $\pm$ 47	420 $\pm$ 28
Aklanyl-[ <sup>3</sup> H]AA-GPE (n = 6)	626 $\pm$ 52	612 $\pm$ 81	

Homogenates from control or stimulated cells were incubated with mixed micelles formed from 2  $\mu$ M of the indicated radiolabeled substrate, egg yolk phosphatidylcholine in a ratio of 3:1 and 200  $\mu$ M Triton X-100 in 100 mM Mops buffer (pH 7.4) containing 20% (v/v) of glycerol and 5 mM CaCl<sub>2</sub>, for 30 min at 37°C. Released fatty acids were extracted by the procedure of Bligh and Dyer [34], separated by TLC and quantified by scintillation spectrometry. Aklanyl-[<sup>3</sup>H]AA-GPE was prepared from [<sup>3</sup>H]AA-prelabeled U<sub>937</sub> cells as described in Materials and Methods and contained approximately 20% of aklyl species.

not possible to assess this residual activity to actual iPLA<sub>2</sub>. Furthermore, when using 10 or 100  $\mu$ M DPPC as substrate, we were unable to show any hydrolysis of this phospholipid, which has been described as a better substrate than arachidonate-containing phospholipids for iPLA<sub>2</sub> [27]. As a consequence, hydrolysis of the three substrates can only be attributed to Ca<sup>2+</sup>-dependent cellular PLA<sub>2</sub>. Surprisingly, the PLA<sub>2</sub> activities did not significantly increase when the homogenates were prepared from cells stimulated with AVP or AIF<sub>4</sub><sup>-</sup> (Table 1). High-molecular-mass cPLA<sub>2</sub> has to bind membranes in a Ca<sup>2+</sup>-dependent manner to become active [10–12]. Therefore, we separated membranes from cytosol of control and stimulated cells to investigate the presence and translocation of cPLA<sub>2</sub> by immunoblot analysis and by assaying the enzyme activity in membrane and cytosol fractions.

The presence of cPLA<sub>2</sub> was demonstrated by immunoblotting with cPLA<sub>2</sub> polyclonal antibody. Reduced mobility of immunodetected cPLA<sub>2</sub> has been linked to its phosphorylated form [18]. Two bands migrating at 100–110 kDa were detected in membrane fraction from control cells, with the lower band (unphosphorylated form) being the larger (Fig. 6). In contrast, the phosphorylated band was larger in membrane fraction from cells previously stimulated with AVP. The two bands were also present in cytosol from stimulated cells, although to a lesser extent, whereas a single band corresponding to unphosphorylated protein was only present in cytosol from control cells. After treatment with AIF<sub>4</sub><sup>-</sup>, a weak single phosphorylated band was observed in both cytosol and membrane fractions.

Translocation of cPLA<sub>2</sub> to membranes was confirmed by assaying the activity. Figure 7 shows that when cells, stimulated or not, were cavitated in the presence of 2 mM Ca<sup>2+</sup>, approximately 70% of PLA<sub>2</sub> activity was associated with membranes. In contrast, when control cells were cavitated in the presence of 2 mM EGTA, the majority of the PLA<sub>2</sub> activity was found in the cytosolic fraction. However, the PLA<sub>2</sub> activity recovered in the membrane fraction increased by almost 100% when cells were stimulated with




FIG. 6. Immunoblot of cPLA<sub>2</sub> in membrane and cytosol fractions of A<sub>7</sub>R<sub>5</sub> cells. After triggering cells with AVP (1  $\mu$ M, 10 min) or AIF<sub>4</sub><sup>-</sup> (5 mM NaF and 10  $\mu$ M AlCl<sub>3</sub>, 120 min), cell extracts were prepared under conditions described in Materials and Methods. Proteins (from 1.25  $10^5$  cells/lane) were subjected to 7.5% SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted with rabbit polyclonal antibody to cPLA<sub>2</sub>. Std, recombinant human cPLA<sub>2</sub>.




FIG. 7. AVP enhances translocation of cPLA<sub>2</sub> activity to membranes. Cytosolic and membrane fractions of control or stimulated A<sub>7</sub>r<sub>5</sub> cells were prepared by N<sub>2</sub> cavitation in the presence of 3 mM CaCl<sub>2</sub> or 2 mM EGTA as described in Materials and Methods. Each fraction (2–5 µg of protein) was assayed with acyl-[<sup>14</sup>C]AA-GPE (2 µM) mixed with egg yolk phosphatidylcholine in a ratio of 3:1 in Mops buffer (pH 7.4) containing 5 mM CaCl<sub>2</sub>. The results are expressed as a percentage of the activity recovered in the membrane fraction related to total activity and are the mean ± SEM of five determinations.

AVP related to control cells, whereas AIF<sub>4</sub><sup>-</sup> did not induce any PLA<sub>2</sub> translocation.

## DISCUSSION

AVP is a potent vasoconstrictor agent that acts on VSMC through a specific V<sub>1</sub> receptor that is coupled to GTP-binding proteins [30]. AVP initiates a series of biochemical events that result in the formation of Ins(1,4,5)P<sub>3</sub> and Ca<sup>2+</sup> mobilization [28–30] concurrently to AA release, which may involve PLA<sub>2</sub> activity. Our results show that the pharmacological tool AIF<sub>4</sub><sup>-</sup>, known as GTP-binding protein activator, also releases AA from VSMC, thereby suggesting activation of PLA<sub>2</sub> through direct GTP-binding protein stimulation. In this paper, we demonstrate that, whereas the cPLA<sub>2</sub> is involved in the release of AA induced by AVP, the appearance of AA in response to AIF<sub>4</sub><sup>-</sup> is a completely different mechanism that does not involve any PLA<sub>2</sub> activity.

The release of [<sup>3</sup>H]AA induced by AVP was rapid up to 3 min, reaching 5–7% of the total radioactivity of cells prelabeled with [<sup>3</sup>H]AA for 60 min. Using fura-2 loaded cells, we verified that AVP induced Ca<sup>2+</sup> mobilization from intracellular pools. This mobilization was followed by an influx of Ca<sup>2+</sup> from the extracellular medium as demonstrated by monitoring Mn<sup>2+</sup> entry. The two waves of Ca<sup>2+</sup> were necessary for AA release since chelators from both intracellular and extracellular Ca<sup>2+</sup> largely prevented the release of labeling. Because cells were labeled for a short

period of time, equilibrium labeling was not reached [48, 49], allowing us to observe transfer reactions between phospholipids. In addition to rapid phosphatidylinositol and phosphatidylcholine hydrolysis, AVP also resulted in [<sup>3</sup>H]AA transfer to ethanolamine-containing phospholipids. The decrease of AA labeling in phosphatidylinositol is consistent with Ins(1,4,5)P<sub>3</sub> formation [30] by phospholipase C and was confirmed by the inhibition of AA release observed when cells were previously treated with neomycin, a phospholipase C inhibitor. The labeling movements among phospholipids also suggested the involvement of PLA<sub>2</sub>. Therefore, we investigated the PLA<sub>2</sub> activities of our cell system.

Using a cell-free system and AA-labeled phospholipid substrates, we observed an important Ca<sup>2+</sup>-dependent PLA<sub>2</sub> activity. We were not able to detect any PLA<sub>2</sub> activity in the absence of Ca<sup>2+</sup> whenever we used plasmalogen phospholipids and DPPC which have been described as substrates for the iPLA<sub>2</sub> [27, 47]. This finding was surprising because iPLA<sub>2</sub> is involved in AA release induced by AVP from A<sub>10</sub> VSM-like cells [26], which are very close to A<sub>7</sub>r<sub>5</sub> VSM-like cells [50]. In A<sub>10</sub> cells, the implication of iPLA<sub>2</sub> was deduced from the inhibitory effect on AA release of the bromoenolactone compound, which is specific for iPLA<sub>2</sub> over a number of PLA<sub>2</sub> [51] and which covalently binds iPLA<sub>2</sub> [51]. Either the two clones contain different amounts of iPLA<sub>2</sub> or the inhibitor compound also acts on as yet unknown targets. Control or AVP-stimulated cells did not secrete any PLA<sub>2</sub> activity, and the activity measured in the cell-free system was insensitive to reducing agents, therefore excluding the implication of sPLA<sub>2</sub> in AA release from A<sub>7</sub>r<sub>5</sub> cells.

The fact that all AA-containing substrates were hydrolyzed speaks in favor of cPLA<sub>2</sub> activity, which was described as not specific for polar head group [10, 15]. Nevertheless, under our incubation conditions using mixed micelles containing egg yolk phosphatidylcholine, there was some preferential hydrolysis of phosphatidylethanolamine over phosphatidylcholine and of alkenyl-acyl-GPE over diacyl-GPE. This preference could account for the more rapid hydrolysis of the AA-richest species since the majority of cellular AA is present in ethanolamine-containing phospholipids [5, 52]. However, the PLA<sub>2</sub> activity of whole homogenate was not increased following AVP stimulation, in contrast to other cell systems in which the enzyme has been implicated in AA release [8, 18]. Conversely, an increase in cPLA<sub>2</sub> was not always accompanied by an increase in AA release [53]. Because translocation of cPLA<sub>2</sub> to membranes [10–12] is necessary for the enzyme to be in contact with its natural substrate, we separated cytosol from membranes and investigated AVP-dependent translocation by Western blot analysis and by assaying the activity. The cPLA<sub>2</sub> antibody revealed that phosphorylated and unphosphorylated forms of cPLA<sub>2</sub> were present in membrane fractions of control and stimulated cells. Both forms of cPLA<sub>2</sub> clearly increased in the membrane fraction with AVP stimulation. Enhance-



ment of cPLA<sub>2</sub> binding to membranes was confirmed by cPLA<sub>2</sub> activity, whose recovery in the membrane fraction was increased by almost 100%. These data demonstrate that with AVP stimulation cPLA<sub>2</sub> was translocated to membrane, and this translocation could be responsible at least in part for the AA release in A<sub>7</sub>r<sub>5</sub> cells.

In contrast, when cells were triggered with AIF<sub>4</sub><sup>-</sup>, AA was released slowly and regularly. The AA release was totally independent of intracellular Ca<sup>2+</sup> mobilization and depended only partly on extracellular Ca<sup>2+</sup>. AIF<sub>4</sub><sup>-</sup> addition induced AA transfer from choline- to ethanolamine-containing phospholipids and a delayed hydrolysis of phosphatidylinositol. Neomycin had no effect on AA release. Clearly, phospholipase C, which induces intracellular Ca<sup>2+</sup> mobilization and is inhibited by neomycin, is not involved in the phosphatidylinositol hydrolysis triggered by AIF<sub>4</sub><sup>-</sup>. Because AA transfer between phospholipids is induced by lysoderivatives [54], the increased transfer rate of [<sup>3</sup>H]AA from phosphatidylcholine to phosphatidylethanolamine is likely to involve lysophosphatidylethanolamine formation through phosphatidylethanolamine hydrolysis by PLA<sub>2</sub>. However, the AA release in response to AIF<sub>4</sub><sup>-</sup> does not appear to implicate cPLA<sub>2</sub> because quinacrine exhibited no inhibitory effect and because cPLA<sub>2</sub>, measured either by Western blot or enzyme activity was neither stimulated nor translocated to membranes. The disappearance of the unphosphorylated band could result from the ability of AIF<sub>4</sub><sup>-</sup> to inhibit phosphatases [55].

Continual AA remodeling between phospholipids of resting cells [48, 49; reviewed in 5, 6] implicates basal PLA<sub>2</sub> activity and acyltransferase and transacylase activities. Recently, Balsinde *et al.* suggested that iPLA<sub>2</sub> was responsible for AA remodeling in macrophagelike cells [56]. We could not show such iPLA<sub>2</sub> in our VSMC. Conversely, some cPLA<sub>2</sub> was bound to membranes of resting VSMC and could account for AA remodeling and basal AA release. When cells were stimulated, translocation of the enzyme to membranes, which occurs with AVP, could result in AA release. Alternatively, because the basal cPLA<sub>2</sub> activity was not increased and even slightly decreased as observed following AIF<sub>4</sub><sup>-</sup> triggering, the appearance of AA in the extracellular medium after AIF<sub>4</sub><sup>-</sup> addition could be the consequence of decreased reacylation mechanisms. Preliminary experiments showing a decrease in AA incorporation into phospholipids of cells exposed to AIF<sub>4</sub><sup>-</sup> support this hypothesis. Further experiments are necessary to determine the mechanisms of this impairment of AA acylation. Is depletion of ATP, as in oxidant-induced AA release from alveolar macrophages [57], involved? Our results do show that direct activation of GTP-binding proteins by AIF<sub>4</sub><sup>-</sup> does not result in cPLA<sub>2</sub> activation or translocation. Rather, AIF<sub>4</sub><sup>-</sup> could increase availability in free AA by preventing AA from being reincorporated.

*supported in part by grants from the Ministère de l'enseignement et de la recherche (MESR, ASV no. 9), the Picasso program and the Institut de la santé et de la recherche médicale (INSERM, CRE 930502). Agnès Cane is a recipient of an MESR fellowship.*

## References

1. Michel J-B, De Roux N, Plissonnier D, Anidjar S, Salzmann J-L and Levy B, Pathophysiological role of the vascular smooth muscle cell. *J Cardiac Pharmacol* **16**: S4-S11, 1990.
2. Danesch U, Weber PC and Sallmayer A, Arachidonic acid increases c-fos and Egr-1 mRNA in 3T3 fibroblasts by formation of prostaglandin E<sub>2</sub> and activation of protein kinase C. *J Biol Chem* **269**: 27258-27263, 1994.
3. Rao GN, Lassegue B, Griendling KK and Alexander W, Hydrogen peroxide stimulates transcription of c-jun in vascular smooth muscle cells: role of arachidonic acid. *Oncogene* **8**: 2759-2764, 1993.
4. Rao GN, Baas AS, Glasgow WC, Eling TE, Runge MS and Alexander RW, Activation of mitogen-activated protein kinases by arachidonic acid and its metabolites in vascular smooth muscle cells. *J Biol Chem* **269**: 32586-32591, 1994.
5. Snyder F, Lee T-C and Blank ML, The role of transacylases in the metabolism of arachidonate and platelet activating factor. *Prog Lipid Res* **31**: 65-86, 1992.
6. Chilton FH, Fonteh AN, Surette ME, Triggiani M and Winkler JD, Control of arachidonate levels within inflammatory cells. *Biochim Biophys Acta* **1299**: 1-15, 1996.
7. Berridge MJ and Irvine RF, Inositol triphosphate, a novel second messenger in cellular signal transduction. *Nature* **312**: 315-321, 1984.
8. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A and Davis RJ, cPLA<sub>2</sub> is phosphorylated and activated by MAP kinase. *Cell* **72**: 269-278, 1993.
9. Qiu Z-H and Leslic CC, Protein kinase C-dependent and -independent pathways of mitogen-activated protein kinase activation in macrophages by stimuli that activate phospholipase A<sub>2</sub>. *J Biol Chem* **269**: 19480-19487, 1994.
10. Clark JD, Lin LL, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, Milona N and Knopf JL, A novel arachidonic acid-selective cytosolic PLA<sub>2</sub> contains a Ca<sup>2+</sup>-dependent translocation domain with homology to PKC and GAP. *Cell* **65**: 1043-1051, 1991.
11. Rehfeldt W, Resh K and Goppelt-Strube M, Cytosolic phospholipase A<sub>2</sub> from human monocytic cells: characterization of substrate specificity and Ca<sup>2+</sup>-dependent membrane association. *Biochem J* **293**: 255-261, 1993.
12. Glover S, Baybutt T, Jonas M, Chi E and Gelb MH, Translocation of the 85-kDa phospholipase A<sub>2</sub> from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/Antigen. *J Biol Chem* **270**: 15359-15367, 1995.
13. Winitz S, Gupta SK, Qian N-X, Heasle LE, Nemenoff RA and Johnson GL, Expression of a mutant G<sub>12</sub>α subunit inhibits ATP and thrombin stimulation of cytoplasmic phospholipase A<sub>2</sub>-mediated arachidonic acid release independent of Ca<sup>2+</sup> and mitogen-activated protein kinase regulation. *J Biol Chem* **269**: 1889-1895, 1994.
14. Kudo I, Murakami M, Hara S and Inoue K, Mammalian non-pancreatic phospholipases A<sub>2</sub>. *Biochim Biophys Acta* **117**: 217-231, 1993.
15. Diez E, Chilton FH, Stroup G, Mayer RJ, Winkler JD and Fonteh AN, Fatty acid and phospholipid selectivity of different phospholipase A<sub>2</sub> enzymes studied by using a mammalian membrane as substrate. *Biochem J* **301**: 721-726, 1994.
16. Sundler R, Winsredt D and Wijkander J, Acyl-chain selectivity of the 85 kDa phospholipase A<sub>2</sub> and of the release process in intact macrophages. *Biochem J* **301**: 455-458, 1994.

*We are grateful to Mariano Sanchez Crespo and Javier Garcia-Sancho for giving us the opportunity of assaying [Ca<sup>2+</sup>], in their laboratory and for their excellent advice. We also thank Dr. Jean-Luc Olivier and the members of his team for providing recombinant cPLA<sub>2</sub>. This study was*

17. Pernas P, Masliah J, Olivier J-L, Salvat C, Rybkine T and Bérézat G, Type II phospholipase A<sub>2</sub> recombinant overexpression enhances stimulated arachidonic acid release. *Biochem Biophys Res Commun* **178**: 1298–1305, 1991.
18. Lin LL, Lin AY and Knopf JL, Cytosolic phospholipase A<sub>2</sub> is coupled to hormonally regulated release of arachidonic acid. *Proc Natl Acad Sci USA* **89**: 6147–6151, 1992.
19. Murakami M, Kudo I and Inoue K, Molecular nature of phospholipases A<sub>2</sub> involved in prostaglandin I<sub>2</sub> synthesis in human umbilical vein endothelial cells. *J Biol Chem* **268**: 839–844, 1993.
20. Pfeilschifter J, Schalkwijk C, Briner VA and Van Den Bosch H, Cytokine-stimulated secretion of group II phospholipase A<sub>2</sub> by rat mesangial cells. *J Clin Invest* **92**: 2516–2523, 1993.
21. Barbour SE and Dennis EA, Antisense inhibition of group II phospholipase A<sub>2</sub> expression blocks the production of prostaglandin E<sub>2</sub> by P388D<sub>1</sub> cells. *J Biol Chem* **268**: 21875–21882, 1993.
22. Roshak A, Sathe G and Marshall LA, Suppression of monocyte 85-kDa phospholipase A<sub>2</sub> by antisense and effects on endotoxin-induced prostaglandin biosynthesis. *J Biol Chem* **269**: 25999–26005, 1994.
23. Vial D and Piomelli D, Dopamine D<sub>2</sub> receptors potentiate arachidonate release via activation of cytosolic, arachidonate-specific phospholipase A<sub>2</sub>. *J Neurochem* **64**: 2765–2772, 1995.
24. Buckley BJ, Barchowsky A, Dolor RJ and Whorton AR, Regulation of arachidonic acid release in vascular endothelium. *Biochem J* **280**: 281–287, 1991.
25. Buckley BJ and Whorton AR, Ca<sup>2+</sup>-independent arachidonic acid release by vascular endothelium requires protein synthesis de novo. *Biochem J* **300**: 449–455, 1994.
26. Lehman JJ, Brown KA, Ramanadham S, Turk J and Gross RW, Arachidonic acid release from aortic smooth muscle cells induced by [Arg<sup>8</sup>]vasopressin is largely mediated by calcium-independent phospholipase A<sub>2</sub>. *J Biol Chem* **268**: 20713–20716, 1993.
27. Ackermann EJ, Kempner ES and Dennis EA, Ca<sup>2+</sup>-independent cytosolic phospholipase A<sub>2</sub> from macrophage-like P388D<sub>1</sub> cells. *J Biol Chem* **269**: 9227–9233, 1994.
28. Grillone LR, Clark MA, Godfrey RW, Stassen F and Crooke ST, Vasopressin induces V<sub>1</sub> receptors to activate phosphatidylinositol- and phosphatidylcholine-specific phospholipase C and stimulates the release of arachidonic acid by at least two pathways in the smooth muscle cell line, A-10. *J Biol Chem* **263**: 2658–2663, 1988.
29. Thibonnier M, Bayer AL, Simonson MS and Kester M, Multiple signaling pathways of V<sub>1</sub>-vascular vasopressin receptors of A<sub>7</sub>15 cells. *Endocrinology* **129**: 2845–2856, 1991.
30. Ito Y, Kozawa O, Tokuda H, Kotoyori J and Oiso Y, Vasopressin induces arachidonic acid release through pertussis toxin-sensitive GTP-binding protein in aortic smooth muscle cells: independence from phosphoinositide hydrolysis. *J Cell Biochem* **53**: 169–175, 1993.
31. Jones LG, Ella KM, Bradshaw CD, Gause KC, Dey M, Wisehart-Johnson AE, Spivey EC and Meier KE, Activations of mitogen-activated protein kinases and phospholipase D in A<sub>7</sub>15 vascular smooth muscle cells. *J Biol Chem* **269**: 23790–23799, 1994.
32. Miwa M, Kozawa O, Suzuki A, Watanabe Y, Shinoda J and Oiso Y, Vasopressin activates phospholipase D through pertussis toxin-insensitive GTP-binding protein in aortic smooth muscle cells: function of Ca<sup>2+</sup>/calmodulin. *Biochem Cell Biol* **73**: 191–199, 1995.
33. Van Renterghem C, Romey G and Lazdunski M, Vasopressin modulates the spontaneous electrical activity in aortic cells (line A<sub>7</sub>15) by acting on three different types of ionic channels. *Proc Natl Acad Sci USA* **85**: 9365–9369, 1988.
34. Bligh EG and Dyer WJ, A rapid method of total lipid extraction and purification. *Can J Biochem Physiol* **37**: 911–917, 1959.
35. El Tamer A, Record M, Fauvel J, Chap H and Douste-Blazy L, Studies on ether phospholipids. I. A new method of determination using phospholipase A<sub>1</sub> from guinea pig pancreas: application to Krebs II ascites cells. *Biochim Biophys Acta* **793**: 213–220, 1984.
36. Gunawan J and Debuch H, Alkenylhydrolase: a microsomal enzyme activity in rat brain. *J Neurochem* **44**: 370–375, 1985.
37. Bartlett GR, Phosphorus assay in column chromatography. *J Biol Chem* **234**: 466–468, 1959.
38. Borenfreund E and Puerner JA, A simple quantitative procedure using monolayer cultures for cytotoxicity assays. *J Tissue Culture Methods* **9**: 7–9, 1984.
39. Villalobos C and Garcia-Sancho J, Caffeine-induced oscillations of cytosolic Ca<sup>2+</sup> in GH3 pituitary cells are not due to Ca<sup>2+</sup> release from intracellular stores but to enhanced Ca<sup>2+</sup> influx through voltage-gated Ca<sup>2+</sup> channels. *Pflügers Archiv* **431**: 371–378, 1996.
40. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**: 248–254, 1976.
41. Ramesha CS and Ives DL, Detection of arachidonoyl-selective phospholipase A<sub>2</sub> in human neutrophil cytosol. *Biochim Biophys Acta* **1168**: 37–44, 1993.
42. Ackermann EJ, Condeelis K and Dennis EA, Inhibition of macrophage Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub> by bromoenol lactone and trifluoromethyl ketones. *J Biol Chem* **270**: 445–450, 1995.
43. Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**: 680–685, 1970.
44. De Carvalho MS, McCormack FX and Leslie CC, The 85-kDa, arachidonic acid-specific phospholipase A<sub>2</sub> is expressed as an activated phosphoprotein in Sf9 cells. *Arch Biochem Biophys* **306**: 534–540, 1993.
45. Nakano T, Ohara O, Teraoka H and Arita H, Group II phospholipase A<sub>2</sub> mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. *FEBS Lett* **261**: 171–174, 1990.
46. Rao GN, Lassegue B, Alexander W and Griendling KK, Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A<sub>2</sub> in vascular smooth-muscle cells. *Biochem J* **299**: 197–201, 1994.
47. Hazen SL, Ford DA and Gross RW, Activation of a membrane-associated phospholipase A<sub>2</sub> during rabbit myocardial ischemia which is highly selective for plasmalogen substrate. *J Biol Chem* **266**: 5629–5633, 1991.
48. Colard O, Breton M and Bérézat G, Arachidonoyl transfer from diacyl phosphatidylcholine to ether phospholipids in rat platelets. *Biochem J* **222**: 657–662, 1984.
49. Joly F, Breton M, Wolf C, Ninio E and Colard O, Heterogeneity of arachidonate and paf-acether precursor pools in mast cells. *Biochim Biophys Acta* **1125**: 305–312, 1992.
50. Kimes BW and Brandt BL, Characterization of two putative smooth muscle cell lines from rat thoracic aorta. *Exp Cell Res* **98**: 349–366, 1976.
51. Hazen SL, Zupan LA, Weiss RH, Getman DP and Gross RW, Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A<sub>2</sub>. *J Biol Chem* **266**: 7227–7232, 1991.
52. Ford DA and Gross RW, Plasmalogen ethanolamine is the major storage depot for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after angiotensin II stimulation. *Proc Natl Acad Sci USA* **86**: 3479–3483, 1989.
53. Akiba S, Abe T and Sato T, Increased cytosolic phospholipase A<sub>2</sub> activity is not accompanied by arachidonic acid lib-

- eration in U46619-stimulated rabbit platelets. *Biochem Mol Biol Int* **35**: 275–281, 1995.
54. Colard O, Breton M and Béréziat G, Induction by lysophospholipids of CoA-dependent arachidonyl transfer between phospholipids in rat platelet homogenates. *Biochim Biophys Acta* **793**: 42–48, 1984.
55. Kanaho Y, Chang PP, Moss J and Vaughan M, Mechanism of inhibition of transducin guanosine triphosphatase activity by vanadate. *J Biol Chem* **263**: 17584–17589, 1988.
56. Balsinde J, Bianco ID, Ackermann EJ, Conde-Frieboes K and Dennis EA, Inhibition of calcium-independent phospholipase A<sub>2</sub> prevents arachidonic acid incorporation and phospholipid remodeling in P388D<sub>1</sub> macrophages. *Proc Natl Acad Sci USA* **92**: 8527–8531, 1995.
57. Sporn PHS and Peters-Golden M, Hydrogen peroxide inhibits alveolar macrophage 5-lipoxygenase metabolism in association with depletion of ATP. *J Biol Chem* **263**: 14776–14783, 1988.